Lisavienna Highlights - newsletter 2 2015 web

Connecting Life Sciences

Highlights 02/2015

Start-up Wave: Newcomers in Vienna

page 3

Life Science City Vienna: Broad Expertise in Medical Devices

page 7

Companies: 22,125 Academia: 11,975 Other organizations: 1,630

Life Science Boomtown Vienna Vienna is currently experiencing a wave of new start-ups. 30 life sciences companies opened their doors within the last two years, thereof 20 biotechnology and medical device companies active in the fields of research, development and manufacturing. In 2014, a total of 480 organizations employed 35,730 people in the life sciences in Vienna. This represents a significant growth as compared to 2012.

Together with BIOCOM, LISAvienna is presenting updated statistics and a new directory in our new publication for you to learn all you need to know about the Viennese life sciences sector.

Economic key facts demonstrate growth 434 companies in biotechnology, pharmaceuticals and the medical device industry employed more than 22,100 people and generated a turnover of nearly 10 billion euros in 2014. This marks a 9% increase as compared to 2012.

Vienna-based companies accounted for 53% of all Austrian life science

W E N

Companies: 434 Academia: 18 Other organizations: 28

Life Science Organizations

480 Employees

35,730 32,872 Revenues

Students

€ 9.9 bn

Publications

4,816

companies, 43% of the entire workforce and 52% of the total industrial turnover of the Austrian life science sector. Almost a third (133 companies) of all Viennese companies in the biotech, pharmaceuticals and medical device business are active in research, development and manufacturing.

These drivers of innovation employed around 10,000 people last year.

Scientific excellence at the heart of Europe Vienna is Austria’s scientific powerhouse – roughly two thirds of all Austrian ERC grantees in the life sciences are based in Vienna. 18 academic research entities have been home to nearly 12,000 highly skilled people in 2014. Last year, they published more than 4,800 papers in peer-reviewed journals and more than 32,800 promising young people picked one of the city’s renowned universities for their studies in the life sciences.

Download the full report at www.LISAvienna.at and order your free print copy via e-mail to office@LISAvienna.at

Dear readers!

Are you already familiar with the latest facts and figures about life sciences in Vienna and our new directory? We are happy to provide you with a completely revised and extended version of the Vienna Life Science Report.

Be invited to order your free print copy and to download the file from our webpage!

Vienna is Austria’s most important place for the life sciences – from research and teaching through to the commercial biotech sector and the pharmaceutical and medical device industries. The continued collaboration with LISA international marketing including the joint survey conducted for the new report was a key advantage to document this fact. 81% of all ERC grantees in the life sciences in Austria have their home base in one of Vienna’s 18 outstanding academic research and teaching organizations. Vienna also accounts for more than half of all life sciences companies in Austria generating more than half of the total turnover.

However, this new “Highlights” edition not only features some of the findings summarized in our report. We also introduce exciting new companies that recently started up in Vienna and provide an outlook on where to meet LISAvienna in the upcoming months worldwide.

The newsflash on page 5 and 6 once more provides powerful examples for success stories: Among others, we feature news from APEIRON Biologics, technological and clinical progress at Apeptico, VC investment in mySugr, a deal at SCARLETRED and the series B financing of Themis. Please also find a photo of our lovely heart-shaped trophy in the newsflash: CSDLabs has been selected for the LISAvienna Medtech Award by the jury in charge of nominating the best business plans submitted in response to the aws Best of Biotech competition.

But for now, enjoy reading and remember: LISAvienna is connecting life sciences.

Peter Halwachs and Johannes Sarx LISAvienna Executive Board

Did you know that…

LISAvienna – Connecting Life Sciences LISAvienna is the joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Science, Research and Economy and the city of Vienna, it contributes to the advancement of life sciences in Vienna.

LISAvienna supports innovative biotech, pharmaceutical and medical technology companies in Vienna that develop and market new products, services and processes. The platform links these companies with development partners and key customers. As a central knowledge carrier, LISAvienna provides input for decisions to advance the life sciences in Vienna and contributes to positioning the city of Vienna as one of the leading European innovation centers.

Please visit our website www.LISAvienna.at to learn more about Vienna as a top location for life sciences!

Our Services • Information & Consulting: Tips and contacts relating to sponsorship, private financing options, infrastructure in Vienna, development partners, leading customers and internationalization • Networking & Matching: Contacts for an improved exchange of experiences and knowledge transfer as well as contact with development partners, leading customers and investors worldwide • Expertise: Analyses, background information, reports and studies relating to life sciences in Vienna • Marketing: Electronic and printed news items from the field of life sciences in Vienna

2015: It’s time to celebrate!

Vienna is home to excellent research institutions which generate knowledge and educate tomorrow’s researchers. This year, the University of Vienna, the University of Veterinary Medicine and TU Wien celebrate significant anniversaries.

…Vienna is a perfect meeting place for medical experts?

Vienna is ranked among the top 3 congress cities worldwide. In 2014, congresses on human medicine continued to dominate this sector in Vienna: 189 national and 109 international congresses in Vienna generated 40% of total overnights resulting from all congresses in 2014. …Vienna is home to experienced partners for clinical research?

27 hospitals are located in the Austrian capital, which has a population of more than 3.7 million people when taking the whole Vienna region into account. In addition to common diseases, expertise regarding rare and undiagnosed diseases is also available.

For further details please check out the Vienna Life Science Report 2015/16!

Currently, Vienna hosts some 190,000 students which make the city the most important place for academic education in the German speaking region. Accordingly, almost 33,000 of these students decided on a study program in the life sciences in 2014 – from human and veterinary medicine to biology, biotechnology and medical engineering.

10 times a year: LISAvienna e-Newsletter 2

Stay updated on hottest news from the life science city Vienna!

Subscribe at www.lisavienna.at/en/e_newsletter

Start-up Wave: Newcomers in Vienna With the help of funds provided by the Austrian Federal Ministry of Science, Research and Economy and the city of Vienna numerous companies open doors in Vienna each year. Promising business ideas are being developed into smart business plans and put into practice. Four of the most recently founded newcomers are introduced below.

The upswing of life sciences companies in Vienna discussed in LISAvienna’s new report for the last two years has not ceased. Tomorrow’s success stories are currently being prepared by creative researchers and resourceful business minds.

LISAvienna’s owners austria wirtschaftsservice and the Vienna Business Agency continuously engage in encouraging and supporting start-ups focusing on biotechnology, medical devices and beyond.

Austrianni GmbH is a new biotechnology company founded in 2015. Its mission is to develop novel antibody-based therapeutics for the prevention and treatment of tuberculosis and other life-threatening infectious diseases. Austrianni has unrestricted access to a powerful antibody discovery platform developed by the California company Trianni. This platform features a full complement of human antibody variable domains that undergo natural V(D)J recombination and somatic hypermutation.

enGenes Biotech GmbH develops customized solutions for the production of recombinant proteins in microbial expression systems by combining next-generation genetic engineering with a broad expertise in bioprocess engineering. Based on a strong understanding of the requirements for the biotech industry and extensive knowledge and method portfolio, enGenes delivers improved host cell lines, plasmid expression vectors and optimized production processes to maximize bio-process efficacy.

HappyMed GmbH contributes to making medical interventions more convenient. Video glasses with earphones allow patients to mentally leave behind displeasing surroundings. This tool helps patients relax and reduce their fears before, during and after treatment. Patients can select from numerous stress relaxation sequences, documentations, concerts, feature films and series stored on a media center. They profit from an improved personal condition in the operating theat-

er, at the dentist, during dialyses or even during cancer therapy.

Mycoplasma Biosafety Services GmbH is a leading contract research organization which is one of the few worldwide suppliers specializing in GMP-compliant mycoplasma biosafety testing of cell banks and biopharmaceutical products including vaccines and ATMPs. The company is also a manufacturer and supplier of ready-to-use high-quality mycoplasma culture media products and mycoplasma reference standards for routine mycoplasma testing, test validations and process validations for mycoplasma removal.

www.austrianni.com www.engenes.cc www.happymed.at www.mycoplasma.cc

Vienna Business Agency: Space for your Company The top 5 pharmaceutical and medical device companies have premises in Vienna and the city is full of promising start-ups in the life sciences. Here, you will find first-class research institutes with long-standing expertise in applied biotechnology, clinical research, engineering and molecular biology.

The Vienna Business Agency offers cost-effective and flexible office space for start-up businesses and young companies. Comprehensive support is available in 15 languages for free and includes coaching in the subjects of founding, financing and expansion. Establish your research, development and manufacturing units in one of Vienna’s special properties or check out undeveloped real estate if your needs necessitate settling, restructuring or business expansion. The outstanding geographical position in the heart of Europe and the highest quality of life in the world also make the city an ideal place to market products across Europe.

Highlights 02/2015

Vienna boosts innovation. Innovative ideas only make a difference once they have survived the journey from the laboratory bench to commercial launch. Tailored support instruments serving the whole value chain are installed in Austria. In Vienna, federal funding is complimented and boosted: Additional 500,000 euros are available for your innovative research project. The Vienna Business Agency supports research projects leading to innovations in products, services or processes and the initiation of cooperative research partnerships.

You are welcome to join Vienna’s life science community.

The Vienna Business Agency welcomes companies of every size and every industry!

Discuss your place in Vienna with our experts: Biotech & pharmaceutical sector: Jürgen Fuchs, Fuchs@LISAvienna.at Medical device sector: Martin Mayer, Mayer@LISAvienna.at

Details on office space, special properties and undeveloped real estate are available online at www.viennabusinessagency.at/property

3

hase II potential p alley h ig h s e ir V RED acqu es Silicon SCARLET roject SOD and go ational p and intern skin drug s all rights ire from u q c O a bH se (S D)

Bulletin d Boar

otein-only dry Apeptico: Carrier-free, pr s & positive powder inhalation particlepeptide phase IIa results of AP301l inhalation ron sized particles for ora The preparation of the mic viously pre tide pep ic eut rap pure the composed exclusively of breaka ptico’s success represents seemed impossible. Ape , the comition add In medicine industry. through for the inhalation AP301the of dy stu ical phase IIa clin pany announced that the ary graft prim of nt tme trea the in results peptide delivered top-line .. wing lung transplantation dysfunction in patients follo cy.at www.viennabusinessagen

ing Gm ismuta RED Hold eroxide D SALK SCARLET uman Sup h t n a EBRA and in D b n recom ration with o iderb p E lla o in c patents o g A . ould healin logics AG w io r B fo t N n ch comO e APEIR nly medte l developm Austria’s o up clinica is d e o e ls ness a sp si D ll u sha minent b ARLETRE ’s most pro ullosa. SC b O s K si W ly r o fo m US jury cted by a n Valley’. pany sele ‘Go Silico m ra g ro p r to ra le acce

AFFiRiS: Vaccine development booste d with 10 million euro s

The vaccine specialist AFFiRiS AG has succes sfully completed its capital increase and raises an additional 10 mil lion euros from existing investors.

convince investors mySugr: Diabetes start-up to

XLHealth ures (San Francisco & Beijing) and Roche Ventures (Basel), iSeed Vent na-based Vien this of th grow nal natio inter for the (Berlin) provide 4.2 million euros over the won H etes. In addition, mySugr Gmb specialist in digital health for diab ia med s euro n millio 2 & Fitness Pitch Day: jury at the Seven Ventures Health transmore etes diab with life e ia AG will mak volume at the ProSiebenSat.1 Med parent for the public.

LISAvien Award 20na Medtech 15

We congra tulate all te ams partic the aws b ipating in usiness p lan compe especially tition BOB CSDLabs – who won Award an our Medte d the two ch B O K U spin-offs TAmiRNA and Syco nium. www.best ofbiotech.a t erg © mySugr GmbH / Anna Clara Holmb

nsis Life bH and Sine ViruSure Gm nnounce partnership a Sciences BV contract

© Peter Ra uchecker

4

al pharmaceutic two leading testing of io ol Together, the rtf a complete po r fe of s rie ork with to labora seeking to w strial clients du in to ruVi es ic s. serv ice provider mber of serv the in er ay pl a reduced nu a strong in Vienna, is nsis, ne Si . es Sure, based ic rv se prion testing d an fers us of vir s, nd field of the Netherla d in Leiden, re istry te em ar ch qu al ad he armaceutic rvices for ph R&D al ic yt al an QC testing se g, osafety testin bi y, 0 og ol 70 bi er ro and mic d serves ov ufacturing an an m ct ra nt and co e. ound the glob customers ar .com www.virusure

I

Vienna

APEIRO N with ant Biologics: start ic o and Sano ancer therapy a f phase I trial nd deal w fi ith Evot APN401, ec based on the

d up e raiseies B c n ie c Bios in ser Themis illion euros Welvestor new in s e to 10 m th y b H plan

collection a patient’s , stimulatio immune c n and sub ells, is be a renown sequent re ing invest ed medic ig -administr a te d a l in a clinic c enter in th ation of munolog al phase e US. Besi ical check I trial perf d e p s o th in ormed at t is blockade Sanofi an n e w a p p s, APEIRO roach for d Evotec triggering to develo N recently The agree p novel sm imannounc ment trigg ed a colla a ll m o le ers two ye cule base boration w Evotec w ars of sub d cancer ith ith the op immunoth stantial re portunity search pa commerc erapies. for both to ym ial milesto e re n ts c eive pre-c for APEIR nes which upon com linical, clin ON and could tota mercializa ical, regu l over 200 latory and tion. million eu ros as we ll as royalti es s

ademia in Science Ac

acts & Figu Vienna – F

d Gmb tment le cience fever e inves is Bios m e With th ngunya h u T ik rs h e C n a rt Pa duct, trials. lington lead pro hase II ress its linical p g c ro to p in to te, andida ccdin eemcia vcaa

A

re

10,376 ther, their high: toge iversities is e, 54% al un m fe g (56% ndin employees estigious fu e pr nc t ie os sc m life the 0 publicarated 4,23 ing. One of the Euroers) gene an level is ch . In pe ar ro s se Eu es re a succ nals in 2014 of sources on iewed jour the key to e, a total in peer-rev Talent as iverouncil. Her students in C ns un h tio 00 ur rc ,0 fo ea 33 rt, repo Vienna pean Res Nabriv with nearly ers from ork of this ates ucced AG Moreover,a Therapeutics Vi anned oun e research the framew t their life enna the clo ienc scits sin lifeg of grants ation abou init es00alone, 54 rm ro ial offe nc pu fo eu ring blic ie in of y sc on 9,0 ed an ,000 Am timilli ovid an po ul th pr the life m s eric ld e an tie is, they fie th De si e sitary ha redSs Shdare t to sescu rding to th ntists in th (AD ), repres 900,0 unof . Accoand g sc them wen The ofing itsiecom ofet Vienna budg esents BOKU moisnfig ecity joined more yo00 total,forces to upgrade the technore,prat nc 14. 28ent sha ie e res In 20 ur sc . of a 14 pu d blic offe itutes the en price of $10.25eper stria. Th by ring euros in 20 AD in Au bef illion ty ore logical of the inst m base r ci und g the 2 at Vienna erwritinengtsdisstcou on ’s 79 yin life otheS, scienc t in ud es12hot spot Muthgasse. The new spen sed nts. All of thescAD me 31,6 In istsinba l stud ientSs ucated so the offeringBwe % ofa.alNa sol nter (VBC). d by 56briv climate t of sities ed ioce hly Na re chamb er ou er iv is 8 unique na andand will boost the improveroug brivina is un (2 in Europe en e 14 Vi 14 a th 20 clinical stage bioph ted at the in 20 t locaarmaceutical compan in Austria e sciences rs accoun eng the lifhnolog ment sciedncinesthe y tsofinbiotec ied uniresearch and grant wyinne ud life age ically plelo en relevan St se ap t ud expres ne sion strains or help to s. st d dev te en an Vi ua pment of nov e C l, th totael ant universities i-infective age 3,123 grad n s science ER to30 r drugs, treaAu e fo life striaiou lif t ser develo d n nts p 66 new te bria ,1 infectioto un st su biolog 59focus ical co antioxi Au ns, of dants l of ac wit e or anti-aging products. al l h a ng ta of ra e% on iv the ple 81mutilin cla foruro a broad ported a antve ibio ss of e high competit es . re Additio s cove rsititics Na ary s infrastructure anr outstanding briva is dev nd 3,400 ogramnally, metab arou olomic pr veterin elo d 14,pin derlining th g an including its 20 un alea , In an d ac ts pro ). l m du ts an ct candidate, lefamu s of the loca gr en m hu to be ing fro the ncefirsstt ud moder lin, tablishmass pleuromutilinViant scie enes spectromete , es ogy tole on a fee for service basis. rshn isolavailab jects, ranng enna ibio ec d attractiv tic in ot ava an bi d l. ilab te d ss le ve for ua an le ne l sys temic administragrad ogy tionstinud th entsans hum ternationa e, biol Get touch icin . NASDAQ and experience the technological power of EQ GmbH rther grow medin e on an in for fu RV s: NB ! demic scen -term basi gineering. field en e th al ing the long ic s ed ad le m so al na en . Vi or ct n se he s e tie http://eq-vibt.boku.ac.at/ in th ality w d universi ientific qu Renowne se lies in its ect to sc iversities with resp scientific ba er-reviewed re pe iversities.

Applied un co of l’s s ta si pi Uni ba ca applied un e e e th th Th is e on on t me to two rees ho rg ed 0 is la as measured e na -b Th T en han Vi ties. ted for 1,26 , Vienna 65. ey accoun join five universi Bio ks forde . In 2014 bagck in 13 d in scitogether th ilife , un E rs 0 publications fo 14 q ve , u 80 20 ni it 4, na U In y e en 2015 Vi s. Th around versity of in Vienn University 0 graduate published a!” e Medical ors. This th searchers ents and 30 ien is , th ar W ud au st ye m st e la ku m ni ior Tech Med In the sa rs as first ished as a d Sciences Ausence pape also establ ty of Applie plied unirted by 42 Vienna was Vienna. ticles repo technical ap of ar n of l al ria st ity e of rs Au th ve t in ni es U e es, rg is 55% tiv e la th e ac th of life scienc tions Vical Faculty ect to the ch organiza versity of requires . W ith resp edical Uni and trian resear ity ut M or rs tp e el ve th ou ch , is ba 04 . th is of its iversity Since 20 es. Clearly, g – ic emphas nomous un life scienc biomediblic fundin the themat en an auto ecular na has be ongoing pu ms lies on ol en ra d m og an in t pr es y es an nc ud forc ie st le r in sc signific jo te life s as e m tie si d renewab in th Both univer boratories e-health an as research gineering, F. Perutz La vacostly. In especially en d no ax l in an M ca g ly e in th gh um emic these hi biology at time-cons , the acad itues – all of can be very C. In 1765 a high technologi -based inst L) at the VB g fields with Maria 16 Vienna FP s vin of (M ol l es ta ev pr to y Em to dl t pi by ra ec isd sp 2014, a ed an re rg e ayr la in ith tiv l Michlm and terd ashaeen lars w / Mic e aw enenn scAvi versity of © LIS employees full particu d the Uni r qualified 957 milde fo Ap tions gave of un l of ed fo ta ity ne to rs ho a et: Unive © EQ GmbH rinary Theresa w ience budg ledge. The e first vete their life sc inary know on the pl icine as th ci na ed en M Vi y e. e s ar bl pu rin in th aila te t am av Ve en C as hm w FH is s es tabl d lion euro plied Scienc ucational es rian applie rgest Aust medicine ed 15, TU Vi, nd is the la ess orld. In 18 es ha w en r nc iv g ie he in tit ot sc ak pe pe com 72, ld of life German-s rnational finally, in 18 ithin the fie ists High inte bioished and of iversity. W se scient s bl un ta ea ne ar es en e Vi d as an in th enna w llence of Resources are its students The exce of Natural that they it educates molecular in the fact e University , which matics and th ed ed or ct at nf iti fle oi in re bi ty ar as g, in )w er ird-p is also KU th ne O gi g (B en in is es ra biog others.

Life Scienc essful in r on applied ogy, amon highly succ ovided thei ng focus biotechnol itutions pr the has a stro st of in w e no 16 nc e, va ific rele a total funds. Her . The scient ey raised technology gether th c- 70 years, BOKU has been biotechnological bers. To research making it one of the finanfor numdoing al rn te ex s in illion euro oldest biotechnology locations worldwide. Amongst its core facilities now is the of 224 m stria Vienna: Rest of Au Vienna Institute of Biotechnology (VIBT), which brings together a broad spectrum tria: Vienna Rest of Aus 81% (54) of BOKU expertise in applied microbiology, food science, applied genetics, chem19% (13) 2) 56% (32,87 istry and water management. An expanded and renewed educational, training and44% (26,294) ) 55% (4,816 testing facility for modern biotechnology was opened ) in 2014.

45% (3,963 Designed as a core ) 75 ,9 (11 % 60 allows students and researchers to engage in facility, the “Bio-Industrial Pilot Plant” ) 40% (7,855

Life

Nabriva Therapeutic s announces closin g of its Initial Public O ffering at NASDAQ

EQ GmbH: Extremophile Center with unique climate-testing laboratory opens doors

strian ERC 80% of all Au s have e life science th in s e te n ra g ienna’s e in one of V s a b e m o h ir ons the arch instituti e s re g in d n outsta

University of Natural Resources and Life Sciences (BOKU) celebrated 70 years of food science and biotechnology

ustria Vienna in A

particularly industry-oriented work.

ts

ERC-Gran Students ns

Publicatio s Employee

More news

Your news placed here

For more news please visit our website www.LISAvienna.at Figure 19:

Highlights 02/2015

Number of tions

C gr

014) and ER

spectively

14) in re ants (until 20

ic institu-

by academ

ts (2 to e-mail news and press releases to news@LISAvienna.at uden , stare Vienna-based organizations invited publications employees, to contribute to LISAvienna’s digital and print media. life science

37

5

new drugs are of greatest Clinical Pipeline ones developing 33 35 importance to both patients and investors. of Dedicated 30 Biotech Companies 25

eye drop program targeting viral infections.

technological and economic challenges

S-target therapeutics GmbH concluded an

that every biotech company is confronted

Clinical pipeline Pipeline Clinical of Dedicated of dedicated Biotech Companies biotech companies Biologics

Drug development not only requires Small Molecules revolutionizing ideas, extensive wet-lab R&D and a clever business Figure 10: Number of therapeutics under model. In the end, clinical studdevelopment at Vienna-based ies are the key to the market and dedicated biotech companies the only possibility to demonstrate safety and efficacy.

(2014)

35

55

33

Biologics

30

20 15

15

15

Small Molecules

25

15

20

10

8 22

Figure 10: Number of therapeutics under

5

3

development at Vienna-based

0

10

dedicated 9 biotech companies

8

(2014) 3

5

4 1

0

0 Preclinical

Phase I

Phase II

Phase III

48

11

13

1

The majority of the dedicated biotech companies in Vienna focuses on medical biotechnology. Whereas 18 firms are active in bioinformatics, industrial and agricultural biotech or other subjects, a staggering 49 of the 67 firms develop drugs and diagnostics. They plow through a wide range of indications while doing so: 41% work in the field of infectious diseases and 27% in cancer. Every fourth company focuses on diseases of the respiratory system, 16% on diseases of the blood and the immune system. Among the 49 dedicated biotech companies concentrating on medical issues, the ones developing new drugs are of greatest importance to both patients and investors.

1

0

Approval Process 1

Preclinical

Phase I

48

11

3

0

Approved

Total

3

77

Three biopharmaceutical products ‘Made in Vienna’ have been brought to the market in recent years: a common cold nasal spray as well as an anti-viral lozenge targeting respiratory viruses, both developed by Marinomed Biotech27 nologie GmbH, and Valneva’s vaccine against Japanese Encephalitis. A total of additional 26 drug candidates are in the clinical pipelines of Vienna-based dedicated bioteccompanies, thereof 19 biologics and seven small molecules (2012 and 2010: 22 candidates).

For details please have a look at the Vienna Life Science Report 2015/16.

Meet LISAvienna • BIO-Europe 2015 Munich, November 2-4, 2015

50.000 Euro

• Medica 2015 Düsseldorf, November 16-19, 2015

aws Temporary Management Financing of complementary management expertise www.awsg.at/maz

• Arab Health 2016 Dubai, January 25-28, 2016 • HIMSS 2016 Las Vegas, February 29 --March 4, 2016 • BIO-Europe Spring Stockholm, April 4-6, 2016

800.000 Euro aws Seedfinancing Financing the start-up phase of life science companies www.seedfinancing.at

• CMEF Spring 2016 Shanghai, April 15-18, 2016 • conhIT 2016 Berlin, April 19-21, 2016 • BioTrinity 2016 London, April 25-27, 2016

200.000 Euro aws PreSeed Financing the pre-start phase www.preseed.at

• BIO International Convention San Francisco, June 6-9, 2016 • BIO-Europe 2016 Cologne, November 7-9, 2016

We bring Life Sciences to Life www.lifescienceaustria.at 6

• Medica 2016 November 14-17, 2016

in cooperation with:

9

4

Phase 13

Life Science City Vienna: Broad Expertise in Medical Devices Demographic changes, technological progress and increased public health awareness let medical device markets grow worldwide.

Vienna is Austria’s hot spot in the medical device industry and a highly attractive location from an international perspective.

The attractiveness of the Austrian capital as a location is underlined by the fact that the top five market leaders of the international medical device industry have an office in Vienna. Apparently, the city can rely on its optimal geographical location in the midst of Europe. Johnson & Johnson, Siemens Healthcare and GE Healthcare, to name but three global players, have a local subsidiary. In 2014, a total of 218 medical device companies were located in Vienna. These generated around 3.2 billion euros in revenues and employed almost 8,200 employees. Nine new companies opened their doors in Vienna in the last two years.

Research, development & production More than 16% of Vienna’s medical device companies perform research, development and manufacturing. Representing the dynamic heart of the sector, these firms generated 1.1 billion euros in turnover in 2014, an increase of 11% when compared to 2012. Among the most important firms operating outstanding medical device divisions is Semperit Technische Produkte GmbH. Sempermed is the largest segment of the Semperit Group and is ranked as one of the leading international manufacturers of medical and industrial gloves.

Dedicated companies 32 ‘dedicated medical device companies’ focus exclusively on medical devices and recorded a total of 1,040 employees in 2014. Together, they achieved a turnover of 159 million euros, which is an increase of 11% compared to two years ago.

Dedicated medical device companies are highly innovative and strategically invest lots of money in R&D every year. Baxter Medical Products GmbH for example offers lifesaving renal and medical products. These include intravenous (IV) solutions, systems and administrative sets, IV infusion parenteral nutrition, perioperative care, pharmacy devices and software, acute renal care, and home and in-center dialysis.

Telemedicine and e-health The largest activity area of the dedicated medical device companies in Vienna is the development of specialized software and other products for telemedicine and e-health solutions. A group of ten companies offers products and services in this field. Founded in 2012 in Vienna, mySugr GmbH specializes in mobile diabetes apps and education services. mySugr’s apps, video based training and remote coaching for children are used by over 370,000 people worldwide and prove that the everyday needs of people with diabetes can be combined with style, innovation and even fun. mySugr is ISO 13485 certified. The mySugr Logbook app is CE marked and is a registered risk class 1 medical device in the US and EU.

Electromechanical medical devices Eight firms are active in the field of electromechanical medical devices. At Miracor Medical Systems GmbH, the so-called PICSO (Pressure controlled Intermittent Coronary Sinus Occlusion) Impulse System is available, which offers new treatment options for cardiovascular diseases. The CEmarked system consists of a driving console and associated catheters, which have positive effects on myocardial function and infarct size in acute heart attack patients. The company is said to be one of the hottest Austrian IPO candidates in the life sciences. As a pioneer in the digital EEG field, Dr. Grossegger & Drbal GmbH’s ‘alpha trace’ has provided numerous hospitals and private practices with cutting-edge equipment in the field of neurology, neurophysiology and sleep medicine.

Assistive products Six companies focus on assistive products for people with disabilities. Otto Bock Healthcare Products GmbH – the medical device company with the most employees in Vienna – is one of the global pioneers in this business area. The company developed the first completely microproces-

sor-controlled lower limb prosthesis system in the world. It is a market leader in medical technology focusing on arm and leg prostheses, and also covers orthotics, mobility solutions and neurorehabilitation. As dynamic growth requires space, the company continuously invests in expanding its Vienna site.

www.alphatrace.at www.baxter.at www.miracormedical.com www.mysugr.com www.ottobock.at www.sempermed.at

Why Vienna?

© Robert Gortana

Dieter Grossegger, CEO of Dr. Grossegger & Drbal Gesellschaft m.b.H., better known as alpha trace Medical Systems

“

After my PhD studies in the USA, I rejected several excellent job offers in the USA and decided to take the hard route and come back to Austria to start my own company. Now, almost 35 years later, I know that my decision to choose Austria and, in our case Vienna, was right. Especially during the last 10 years, Vienna, a cultural metropolis and a city with excellent quality of life, has progressed to become an innovative center with an excellent research infrastructure and cooperation perspectives.” www.alphatrace.at

7

Baxalta’s Corner Stone: Commitment to Innovation

© Baxalta

Baxalta’s premises in Austria represent the company’s largest facilities worldwide. About a quarter of all employees are based here. Austria is home to one of Baxalta’s three centers for research and development. Pharmaceutical production is carried out in seven countries. The largest production site however is the Vienna region where products worth 700 million euros are produced each year of which 90% is allotted for export.

A highlight in Baxalta’s current pipeline is Vonvendi which is the first recombinant drug worldwide for the treatment of von Willebrand Disease. Baxalta expects FDA approval this year. Von Willebrand Disease is the most common inherited blood clotting disorder and Vonvendi represents the very first innovative treatment option in more than two decades. The von Willebrand factor is the largest protein in blood plasma and is responsible for stabilizing of blood clotting factor VIII, as well as for the quick repair of blood vessel damages. The production of this highly sensitive protein requires

LISAvienna Life Science Austria Vienna Walcherstrasse 11A 1020 Vienna, Austria

PHONE FAX E-MAIL WEB

Baxalta also carries out intensive research to develop a somatic gene therapy for patients suffering from hemophilia A which will represent another revolution for the treatment of blood clotting disorders.

es

ploye

00 em

• > 4,0

est co

• Larg

ation

y loc mpan

wide

world

ters

D cen

ree R&

s n euro millio 0 0 7 h year wort ducts a each • Pro Vienn in d e c produ e t shar expor % 0 9 • >

of th • One

Timely structures for innovation Baxalta’s roots in Austria date back to the 1950s when Johann Eibl, Otto Schwarz and Wilhelm Auerswald founded an institute that later on lead to the foundation of Immuno AG which has been acquired by Baxter. Prior to establishing Baxalta, Baxter completed the sale of its commercial vaccines business and related manufacturing facilities to Pfizer Inc. Baxter’s vero cell technology for vaccine production and all assets related to the platform, including production facilities and vaccines for H5N1, H1N1 and seasonal influenza and investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus have been sold to Nanotherapeutics Inc. Today, Baxter focuses on lifesaving hospital products and essential renal products for inpatient and home care whereas Baxalta advances biopharmaceuticals.

www.baxalta.com

+ 43 (0) 1 50175 358 + 43 (0) 1 50175 900 office@LISAvienna.at www.LISAvienna.at

Why Vienna?

Michael Heinrich, Head of Corporate Communications at Baxalta in Austria

“

Besides the fact that our foundational roots are here in Vienna, we were always able to find the highly qualified workforce we needed for our challenging biotechnology environment at this location.

That means we need quality in all aspects – quality of life as well as quality of infrastructure.

The almost unique combination of all three Baxalta core processes R&D, manufacturing and marketing at one location, generates a continuous innovation pipeline.”

LISAvienna is the joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Science, Research and Economy and the city of Vienna, LISAvienna contributes to the advancement of life sciences in Vienna.

crevo.net

Revolutions for blood clotting disorders

extremely careful handling. Baxalta’s experts in the Vienna region (Orth/ Danube) succeeded in developing the appropriate production processes.

ia

Austr

© Baxalta

Baxalta is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Baxalta’s broad and diverse pipeline includes biologics with groundbreaking mechanisms and advanced technology platforms such as gene therapy. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. The company plans to launch by 2020 a total of 20 new products. Plasma fractionation facilities and plants for the production of recombinant proteins located in the Vienna region are of high importance in this regard. Extensive know-how covering all phases of the R&D process regarding new medicines in hematology and immunology has been developed in Austria. Further research in oncology will be the focus of attention in the future, especially in terms of the early phases of development.

ta in Baxal